Literature DB >> 16278810

Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin.

Dirk Lebrecht1, Aikaterini Kokkori, Uwe-Peter Ketelsen, Bernhard Setzer, Ulrich A Walker.   

Abstract

Doxorubicin causes a chronic cardiomyopathy. Although the exact pathogenesis is unknown, recent animal data suggest that somatically acquired alterations of mitochondrial DNA (mtDNA) and concomitant mitochondrial dysfunction play an important role in its onset. In this study, skeletal and myocardial muscles were examined from human autopsies. Compared to controls (n = 8), doxorubicin-exposed hearts (n = 6) showed low absolute enzyme activity of mtDNA-encoded nicotinamide adenine dinucleotide hydrogen dehydrogenase (NADH DH, 79% residual activity, p = 0.03) and cytochrome c oxidase (COX, 59% residual activity, p < 0.001), but not of succinate dehydrogenase (SDH), which is encoded exclusively by nuclear DNA. NADH DH/SDH and COX/SDH ratios were 37% (p < 0.001) and 27% (p < 0.001) of controls. Expression of the mtDNA-encoded subunit II of COX was reduced (82%, p = 0.04), compared to its unchanged nucleus-encoded subunit IV. MtDNA-content was diminished (56%, p = 0.02), but the 'common' mtDNA-deletion was increased (9.2-fold, p = 0.004). Doxorubicin-exposed hearts harboured numerous additional mtDNA rearrangements lacking direct repeats. They contained elevated levels of malondialdehyde (MDA) (p = 0.006, compared to controls), which correlated inversely with the COX/SDH ratio (r = -0.45, p = 0.02) and the mtDNA-content (r = -0.75, p = 0.002), and correlated positively with the levels of the 'common' deletion (r = 0.80, p < 0.001). Doxorubicin-exposed hearts also contained the highest levels of superoxide (p < 0.001, compared to controls), which correlated negatively with the mtDNA-encoded respiratory chain activities, such as the COX/SDH ratio (r = -0.57, p = 0.02) and the NADH/SDH ratio (r = -0.52, p = 0.04), as well as with the mtDNA content (r = -0.69, p = 0.003), and correlated positively with the frequency of the 'common' deletion (r = 0.76, p < 0.001) and the MDA levels (r = 0.86, p < 0.001). Doxorubicin-exposed hearts contained electron-dense deposits within mitochondria. Hearts exposed to other anthracyclines (n = 6) or skeletal muscle (all groups) had no mitochondrial dysfunction. Doxorubicin, unlike other anthracyclines, augments lipid peroxidation, induces mtDNA mutations and decreases mtDNA content in human hearts. These lesions have an impact on mitochondrial function and could be of importance in the pathogenesis of clinical cardiomyopathy. Copyright 2005 Pathological Society of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16278810     DOI: 10.1002/path.1863

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  57 in total

1.  [Kearns-Sayre syndrome : a mitochondrial disease (OMIM #530000)].

Authors:  W J Mayer; M Remy; G Rudolph
Journal:  Ophthalmologe       Date:  2011-05       Impact factor: 1.059

2.  Androgen receptor counteracts Doxorubicin-induced cardiotoxicity in male mice.

Authors:  Yasumasa Ikeda; Ken-ichi Aihara; Masashi Akaike; Takashi Sato; Kazue Ishikawa; Takayuki Ise; Shusuke Yagi; Takashi Iwase; Yuka Ueda; Sumiko Yoshida; Hiroyuki Azuma; Kenneth Walsh; Toshiaki Tamaki; Shigeaki Kato; Toshio Matsumoto
Journal:  Mol Endocrinol       Date:  2010-05-25

3.  Prkdc participates in mitochondrial genome maintenance and prevents Adriamycin-induced nephropathy in mice.

Authors:  Natalia Papeta; Zongyu Zheng; Eric A Schon; Sonja Brosel; Mehmet M Altintas; Samih H Nasr; Jochen Reiser; Vivette D D'Agati; Ali G Gharavi
Journal:  J Clin Invest       Date:  2010-10-18       Impact factor: 14.808

4.  Mitochondrial DNA content in paired normal and cancerous breast tissue samples from patients with breast cancer.

Authors:  Alex Xiu-Cheng Fan; Ramin Radpour; Mahdi Montazer Haghighi; Corina Kohler; Peng Xia; Sinuhe Hahn; Wolfgang Holzgreve; Xiao Yan Zhong
Journal:  J Cancer Res Clin Oncol       Date:  2009-01-06       Impact factor: 4.553

Review 5.  Rodent models of heart failure: an updated review.

Authors:  A C Gomes; I Falcão-Pires; A L Pires; C Brás-Silva; A F Leite-Moreira
Journal:  Heart Fail Rev       Date:  2013-03       Impact factor: 4.214

6.  Redox proteomic identification of HNE-bound mitochondrial proteins in cardiac tissues reveals a systemic effect on energy metabolism after doxorubicin treatment.

Authors:  Y Zhao; S Miriyala; L Miao; M Mitov; D Schnell; S K Dhar; J Cai; J B Klein; R Sultana; D A Butterfield; M Vore; I Batinic-Haberle; S Bondada; D K St Clair
Journal:  Free Radic Biol Med       Date:  2014-03-12       Impact factor: 7.376

Review 7.  Cardiovascular diseases in survivors of childhood cancer.

Authors:  Neha Bansal; Javier G Blanco; Umesh C Sharma; Saraswati Pokharel; Shannon Shisler; Steven E Lipshultz
Journal:  Cancer Metastasis Rev       Date:  2020-03       Impact factor: 9.264

8.  Visnagin-a new protectant against doxorubicin cardiotoxicity? Inhibition of mitochondrial malate dehydrogenase 2 (MDH2) and beyond.

Authors:  Lei Xi
Journal:  Ann Transl Med       Date:  2016-02

Review 9.  Chemotherapy and cardiotoxicity.

Authors:  Howard Broder; Roberta A Gottlieb; Norman E Lepor
Journal:  Rev Cardiovasc Med       Date:  2008       Impact factor: 2.930

10.  Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q.

Authors:  Karunakaran Chandran; Deepika Aggarwal; Raymond Q Migrino; Joy Joseph; Donna McAllister; Eugene A Konorev; William E Antholine; Jacek Zielonka; Satish Srinivasan; Narayan G Avadhani; B Kalyanaraman
Journal:  Biophys J       Date:  2009-02-18       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.